These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 17668422)

  • 1. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer.
    Tomlinson DC; Baldo O; Harnden P; Knowles MA
    J Pathol; 2007 Sep; 213(1):91-8. PubMed ID: 17668422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
    Knowles MA
    World J Urol; 2007 Dec; 25(6):581-93. PubMed ID: 17912529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
    Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
    J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer.
    Neuzillet Y; van Rhijn BW; Prigoda NL; Bapat B; Liu L; Bostrom PJ; Fleshner NE; Gallie BL; Zlotta AR; Jewett MA; van der Kwast TH
    Virchows Arch; 2014 Aug; 465(2):207-13. PubMed ID: 24880661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
    Al-Ahmadie HA; Iyer G; Janakiraman M; Lin O; Heguy A; Tickoo SK; Fine SW; Gopalan A; Chen YB; Balar A; Riches J; Bochner B; Dalbagni G; Bajorin DF; Reuter VE; Milowsky MI; Solit DB
    J Pathol; 2011 Jun; 224(2):270-9. PubMed ID: 21547910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
    Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
    BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
    Guancial EA; Werner L; Bellmunt J; Bamias A; Choueiri TK; Ross R; Schutz FA; Park RS; O'Brien RJ; Hirsch MS; Barletta JA; Berman DM; Lis R; Loda M; Stack EC; Garraway LA; Riester M; Michor F; Kantoff PW; Rosenberg JE
    Cancer Med; 2014 Aug; 3(4):835-44. PubMed ID: 24846059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer.
    Bertz S; Abeé C; Schwarz-Furlan S; Alfer J; Hofstädter F; Stoehr R; Hartmann A; Gaumann AK
    Virchows Arch; 2014 Dec; 465(6):687-95. PubMed ID: 25326864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
    Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
    J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
    Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
    Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
    Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma.
    Bakkar AA; Allory Y; Iwatsubo Y; de Medina SG; Maille P; Khreich N; Riou A; Leroy K; Vordos D; Abbou CC; Andujar P; Billebaud T; Chammings S; Conso F; De La Taille A; Fontaine E; Gattegno B; Ravery V; Sibony M; Radvanyi F; Chopin DK; Pairon JC
    Mol Carcinog; 2010 Jan; 49(1):25-31. PubMed ID: 19722178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.
    Fischbach A; Rogler A; Erber R; Stoehr R; Poulsom R; Heidenreich A; Schneevoigt BS; Hauke S; Hartmann A; Knuechel R; Veeck J; Gaisa NT
    Histopathology; 2015 Apr; 66(5):639-49. PubMed ID: 24898159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
    Wang L; Gong Y; Saci A; Szabo PM; Martini A; Necchi A; Siefker-Radtke A; Pal S; Plimack ER; Sfakianos JP; Bhardwaj N; Horowitz A; Farkas AM; Mulholland D; Fischer BS; Oh WK; Sharma P; Zhu J; Galsky MD
    Eur Urol; 2019 Nov; 76(5):599-603. PubMed ID: 31272788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.